Skip to main content
. 2018 Feb 16;19(2):590. doi: 10.3390/ijms19020590

Figure 4.

Figure 4

Figure 4

LTTs are more resistant to induction of cisplatin-induced apoptosis. (a) Relative fold change of BCL2, BCL-xL, BCL-xS, and BIRC5/Survivin mRNA expression in LTTs compared to their parental cell lines was measured by qRT-PCR. Expression levels in the untreated parental cells were set as 1. For endogenous expression data of parental UCCs see Figure S1d. SDHA was used as a reference gene and relative expression was calculated by the 2−ΔΔCt method. Values represent the mean ± SD of three independent experiments. BIRC5/Survivin, BCL-xL, BCL-xS (b), PARP, cleaved PARP, Caspase-3, and cleaved Caspase-3 (c) protein expression was detected in either untreated or IC50 doses treated parental UCCs and compared with LTTs under either untreated conditions or treated with maintenance or IC50 cisplatin concentration for 72 h. As a loading control, α-Tubulin was detected. One representative immunoblot is shown from two independent experiments. (d) Caspase 3/7 activity was measured in parental UCCs untreated or treated with IC50 cisplatin concentration and LTTs treated with maintenance or IC50 cisplatin concentration for 72 h. Values were adjusted to cell viability as measured by CellTiter Glo. Values represent the mean ± SD of two independent experiments. * p < 0.05.